
    
      This will be a multicenter, single-dose, dose-escalation study. The study will be in 2 parts:
      the first, Part A, will be an open label evaluation of single doses of four dose cohorts and
      the second, Part B will be a randomized, double-blind, placebo-controlled, single-dose,
      dose-escalation study of two dose cohorts. Patients who are undergoing cadaveric kidney
      transplantation and are at risk for development of DGF, based upon known risk factors, will
      be eligible to participate in the study. A maximum of 24 patients will be enrolled in Part A
      of the study. 60 patients will be enrolled in Part B.
    
  